Table 1 Characteristics of documented male patients with advanced prostate cancer (total number = 1273)

Demographic data: mean (minimum, maximum)

Age (years)

75 (50, 97)

Weight (kg)

81 (45, 160)

Height (cm)

175 (157, 198)

Diagnosis/findings: mean

Time since first diagnosis (months)

33

Biopsy: Number of cores

8.2

   Number of positive cores

4.5

cT1-2, %

44

cT3-4, %

32

M+, %

20

Gleason grade (1-5)

3.4

Gleason sum (2-10)

6.8

Therapy with GnRH analogues: number of patients (%)

First-time treatment

610 (48)

Pre-treatment*

652 (51)

   3 monthly leuprolide acetate

210 (32.2)

   Leuprolide acetate, Takeda Pharmaceutical

168 (25.8)

   Goserelin acetate, AstraZenca

107 (16.4)

   Buserelin acetate, Sanofi-Aventis

97 (14.9)

   1 monthly leuprolide acetate

27 (4.1)

   Leuprorelin acetate, Takeda Pharmaceutical

21 (3.2)

   Other drugs

22 (3.4)

   Missing data

15 (2.3)